Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W
Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine
Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the
Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study.
A new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is looking to help ‘individualise’ treatment for diabetes patients by better predicting t